

Change in Coverage Status to Generic Fluticasone HFA and QVAR Redihaler Begins on Dec. 15, 2023

The drug manufacturer, GlaxoSmithKline, announced a discontinuation of brand Flovent HFA (fluticasone propionate inhalation aerosol) and Flovent Diskus (fluticasone propionate inhalation powder) products on Dec. 31, 2023. Texas Medicaid anticipates the supply of these products will be unavailable beginning in early 2024. These drugs are used to treat and prevent asthma.

To address a shortage of these drugs, Texas Medicaid will make generic fluticasone HFA and Qvar Redihaler, a similar drug, available to Texas Medicaid clients without prior authorization. Also, brand name Flovent HFA and Flovent Diskus products will continue to be available on the Texas Medicaid formulary until the existing supply of these drugs runs out.

The Texas Health and Human Services Commission will cover the following drugs without requiring prior authorization starting December 15.

Drug Name	National Drug Code (NDC)
FLUTICASONE PROP HFA 44 MCG	66993007896
FLUTICASONE PROP HFA 110 MCG	66993007996
FLUTICASONE PROP HFA 220 MCG	66993008096
QVAR REDIHALER 40 MCG	59310030240
QVAR REDIHALER 80 MCG	59310030480